Patents by Inventor Mark X. Sliwkowski

Mark X. Sliwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10556966
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20190374547
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 12, 2019
    Applicant: GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • Publication number: 20190177429
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10314846
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 11, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10179820
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20180326062
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10058613
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: August 28, 2018
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Publication number: 20180185486
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 9963517
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 8, 2018
    Assignees: Genentech, Inc., University of Turku
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • Publication number: 20170274092
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 28, 2017
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20170174782
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 18, 2016
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20170136026
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 18, 2017
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • Publication number: 20170095570
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 9518118
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 9327035
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: May 3, 2016
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
  • Publication number: 20160096893
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 11, 2015
    Publication date: April 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20160075798
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 17, 2016
    Applicants: UNIVERSITY OF TURKU, GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • Publication number: 20150086545
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: Mark X Sliwkowski, Stephen M Kelsey
  • Publication number: 20140271634
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and a HER3/EGFR inhibitor (such as MEHD7945A). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicants: The Regents of the University of California, Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Wolfgang Michael Korn
  • Publication number: 20140193414
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Application
    Filed: December 9, 2013
    Publication date: July 10, 2014
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski